Wall Street analysts expect Agilent Technologies (A) to post quarterly earnings of $1.25 per share in its upcoming report, which indicates a year-over-year decline of 12.6%. Revenues are expected to be $1.56 billion, down 6.6% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company announ ...

Agilent Technologies (A) recently launched its new ProteoAnalyzer system at the Singapore Cell and Gene Therapy Pan Asia Summit.ProteoAnalyzer is an automated parallel capillary electrophoresis solution, enabling rapid, high-resolution protein analysis with minimal sample consumption, facilitating faster discoveries for researchers.This biomolecular platform aims to elevate translational research from compound to novel applications. The platform includes easy-to-use QC workflows for assessing protein size a ...

These are solid stocks that have all generated 10-year returns in excess of 200%.The S&P 500 has remained red hot, achieving gains of nearly 15% through the first six months of 2024. Healthcare stocks have performed well, but not nearly to the same extent -- the Healthcare Select Sector SPDR ETF has risen by 7% during the first half of this year.Healthcare stocks may not generate as much excitement as other growth stocks, but there are some solid options that you can buy and hold, not just for the second pa ...

A month has gone by since the last earnings report for Agilent Technologies (A) . Shares have lost about 0.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Agilent due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Agilent Q2 Earnings Beat EstimatesAgilent Technolo ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Agilent Technologies, Inc. (A) is an application-focused solutions provider to the life sciences, diagnostics, and applied chemical markets. The Zacks Consensus Estimate for its current year earnings has been revised 4% downward over the last 60 days.Avis Budget Group, Inc. (CAR) is a car and truck rental company. The Zacks Consensus Estimate for its current year earnings has been revised 19.6% downward over the last 60 days.B&G Foods ...

Agilent Technologies (A) is leaving no stone unturned to capitalize on growth opportunities present in the global mass spectrometry (MS) market, which, per a Mordor Intelligence report, is expected to hit $6.77 billion in 2024 and reach $9.17 billion by 2029, witnessing a CAGR of 6.3% between 2024 and 2029.In this regard, the company recently introduced two new products, namely the Agilent 7010D Triple Quadrupole gas chromatography (GC)-MS System and the Agilent ExD Cell.The Agilent 7010D Triple Quadrupole ...

会议主要讨论的核心内容 公司业绩和指引 - 公司第二季度收入下降7%,符合预期,利润下降4%超出预期 [4] - 公司连续三个季度实现正的订单增长,第一季度七个季度以来首次实现订单增长,但增速低于预期,导致下调下半年指引 [5] - 公司维持5%-7%的长期增长目标,预计市场增长3%-5% [14][18][19] 中国市场 - 中国市场第二季度收入下降,主要受食品、环境和学术领域疲软影响,化学和先进材料领域表现强劲 [21][22][23] - 中国政府即将推出新的刺激计划,预计将涉及制药、半导体、环境等多个领域,但公司暂未在下半年指引中考虑该因素带来的正面影响 [24][25][26][27][28][29] 制药仪器业务 - 制药仪器业务从第二季度开始出现下滑,主要是资金释放速度慢于预期,但未见预算削减 [30][31][32][33][34][35] - 预计未来12-24个月内将出现制药客户更新换代的需求高峰 [41][42] NASD业务 - NASD业务第二季度收入下滑中单位数,主要是商业销量下降,但临床试验项目数创历史新高 [46][47][48] - 公司继续加大NASD业务产能投入,并与大型制药客户保持密切合作 [52][53][54][55] 其他新兴领域 - 公司在PFAS、半导体和电池等新兴领域持续加大投入,看好未来增长潜力 [73][74][75] - 公司将继续关注并购机会,以拓展在生物医药等领域的布局 [66][67] 问答环节重要的提问和回答 问题1 **Tycho Peterson 提问** 公司是否考虑在年末进行更大规模的预算释放 [43] **Robert McMahon 回答** 如果客户预算未发生变化,公司预计今年年末的预算释放将超过去年 [44] 问题2 **Tycho Peterson 提问** 公司如何看待NASD业务商业销量下滑的原因 [49] **Robert McMahon 回答** 公司产品和技术并未出现问题,下滑主要是客户自身的商业策略调整所致 [50] 问题3 **Tycho Peterson 提问** 公司是否考虑通过并购来拓展NASD业务的客户群 [59][60] **Robert McMahon 回答** 公司正在通过拓展新客户和新适应症来实现NASD业务的客户多元化 [60]

Agilent Technologies, Inc. (NYSE:A) Jefferies 2024 Global Healthcare Conference June 5, 2024 8:30 AM ET Company Participants Robert McMahon - Senior Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson All right, we're good to go. Good morning, everyone. I'm a Tycho Peterson from the life science team here at Jefferies. Pleased to introduce Bob McMahon from Agilent. Robert McMahon Great, thanks. Thanks, Michael. Good to see you. Great to be here ...

Have you assessed how the international operations of Agilent Technologies (A) performed in the quarter ended April 2024? For this scientific instrument maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajecto ...

公司财务表现 - 2024年4月30日，公司净收入为15.73亿美元，同比下降8%[71] - 2024年4月30日，公司净利润为3.08亿美元，同比增长2%[72] - 2024年4月30日，公司支付的现金股利为每股0.236美元，总计6900万美元[72] - 公司2023年启动了一项重组计划，预计将在2024年底前实现每年成本节约8千万美元[75] - 公司2024年5月宣布了新的重组计划，预计将在2024年底前实现每年成本节约1亿美元[76] 业务表现 - 公司的生命科学和应用市场业务提供液相色谱、质谱等解决方案[86] - 公司的关键产品类别包括液相色谱系统、气相色谱系统、质谱仪等[87] - 公司的生命科学和应用市场业务提供应用专注的解决方案[86] - 公司的液相色谱和质谱产品在关键产品类别中占据重要地位[87] - 2024年4月30日，生命科学和应用市场业务的净收入分别下降了14%和12%[88] - 2024年4月30日，美洲地区的收入下降了9%，欧洲地区下降了9%，亚太地区下降了19%[88] 成本与支出 - 公司在2024财年第一季度宣布对运营部门进行调整[85] - 研发支出在2024年4月30日的三个月内下降了9%[90] - 销售、一般和行政支出在2024年4月30日的三个月内下降了5%[90] - 研发支出在2024年4月30日的三个月内下降了12%[97] - 销售、一般和行政支出在2024年4月30日的三个月内下降了7%[97] - 研发支出在2024年4月30日结束的三个月和六个月中分别下降了12%和9%[99] 其他财务信息 - 净现金流入运营活动为2024年4月30日结束的六个月为8.18亿美元，较去年同期的6.94亿美元有所增长[105] - 毛利率在2024年4月30日结束的三个月和六个月中分别增加了3个百分点[103] - 预计2024年全年总资本支出约为4亿美元[107] - 公司计划扩大在科罗拉多州弗雷德里克的核酸类治疗产品生产制造能力[108] - 公司2023年回购计划授权购买高达20亿美元的普通股，截至2024年4月30日，已回购并注销了1.594万股，金额为2.3亿美元[109] - 公司2024年回购计划授权购买高达20亿美元的普通股，将于2024年8月1日生效[109] - 公司在2024年4月30日和2023年4月30日分别支付了每股0.472美元和0.450美元的现金股息[109] - 公司在2023年4月30日支付了6500万美元与Resolution Bioscience收购相关的技术里程碑费用[109] - 公司于2024年4月30日未在信用设施和商业票据计划下进行借款[109] - 公司长期负债中包括1.15亿美元和1.62亿美元的其他长期负债，其中有64百万美元和68百万美元与不确定的税务立场相关[110] - 公司在2024年4月30日进行了对外汇风险和利率风险的敏感性分析，结果显示对公司的财务状况没有实质影响[111]